Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis

Autor: Kirk Easley, Ryan Robinson, Zachary Fausel, Robert Bowers, Kenneth Mautner
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Visual analogue scale
Adipose
Arthritis
Adipose tissue
Bone Marrow Cells
Stem cells
Osteoarthritis
Injections
Intra-Articular
03 medical and health sciences
0302 clinical medicine
Bone marrow aspirate
Human Clinical Article
Quality of life
medicine
Humans
Bone marrow
Prospective Studies
lcsh:QH573-671
Bone Marrow Transplantation
Retrospective Studies
Adult stem cells
lcsh:R5-920
lcsh:Cytology
business.industry
Significant difference
Cell Biology
General Medicine
Middle Aged
Osteoarthritis
Knee
Prognosis
medicine.disease
Adipose stem cells
Surgery
030104 developmental biology
medicine.anatomical_structure
Adipose Tissue
Quality of Life
Mesenchymal stem cells
Female
lcsh:Medicine (General)
business
030217 neurology & neurosurgery
Developmental Biology
Zdroj: Stem Cells Translational Medicine, Vol 8, Iss 11, Pp 1149-1156 (2019)
Stem Cells Translational Medicine
ISSN: 2157-6580
2157-6564
Popis: This study aimed to determine whether autologous orthobiologic tissue source affects pain and functional outcomes in patients with symptomatic knee osteoarthritis (OA) who received microfragmented adipose tissue (MFAT) or bone marrow aspirate concentrate (BMAC) injection. We retrospectively reviewed prospectively collected data from patients who received BMAC or MFAT injection for symptomatic knee OA. Patients completed baseline and follow-up surveys. Each survey included the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, Emory Quality of Life (EQOL) questionnaire, and Visual Analog Scale (VAS) for pain. The follow-up responses were compared with baseline for all patients and between BMAC and MFAT groups. A total of 110 patients met inclusion criteria, with 76 patients (BMAC 41, MFAT 35) and 106 knees (BMAC 58, MFAT 48) having appropriate follow-up data. The BMAC group included 17 females and 24 males, with a mean age of 59 ± 11 years. The MFAT group included 23 females and 12 males, with a mean age of 63 ± 11 years. Minimum follow-up time was 0.5 years. Mean follow-up time was 1.80 ± 0.88 years for BMAC and 1.09 ± 0.49 years for MFAT. Both groups had significant improvement in EQOL, VAS, and all KOOS parameters preprocedure versus postprocedure (p
Databáze: OpenAIRE
Externí odkaz: